contracts and grants.
-- Regulus Therapeutics
o Regulus, Isis' joint venture formed in September 2007, is focused on
developing microRNA therapeutics, as a new approach to target the
pathways of human disease. Last month, Regulus entered into a
strategic alliance with GSK that could provide up
to nearly $600 million to Regulus to develop microRNA-targeted
therapeutics to treat inflammatory disease.
-- Regulus received a $20 million upfront payment, including a
$15 million option fee and payment for a $5 million note that
will convert into Regulus common stock under certain
-- The alliance provides GSK with an option to license drug
candidates directed at four different inflammatory disease
-- Regulus will receive up to $144.5 million in development,
regulatory and sales milestone payments for each
microRNA-targeted drug discovered and developed as part of the
-- Regulus will also receive tiered royalties up to double digits
on sales of drugs resulting from the alliance.
At 08:30 a.m. Eastern Time today, May 12, Isis will conduct a live webcast conference call to discuss this earnings release and related activities. Interested parties may access the webcast at http://www.isispharm.com, or listen to the call by dialing 877-548-7906. A webcast replay will be available for a limited time at the same address.
About Isis Pharmaceuticals, Inc.
Isis is exploiting its expertise in RNA to discover and develop novel
drugs for its product pipeline and for its partners. The C
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved